Immunogenicity of Twinrix™ in older adults: A critical analysis

Expert Review of Vaccines

Volumn 2, Issue 1, 2003, Pages 9-14

  Stoffel, Michel ^a   Lievens, Marc ^a   Dieussaert, Ilse ^a   Martin, Isabelle ^a   André, Francis ^a  

^a GSK   (Belgium)

Author keywords

Elderly; HBV HAV combined vaccine; Immune response

Indexed keywords

ANTIBODY; HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B VACCINE; VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROLOGY; VACCINATION; AGE; ARTICLE; BIOSYNTHESIS; BLOOD; COMORBIDITY; FACTUAL DATABASE; IMMUNIZATION; IMMUNOLOGY; META ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; CLINICAL TRIALS; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; VACCINATION; VACCINES, COMBINED;

EID: 0038330757     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.1.9     Document Type: Review

References (23)

1. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 272, 885-889 (1994).
2. André F, Van Damme P, Safary A, Banarvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Fxpert Rev. Vaccines 1(1), 9-23 (2002). Discusses 10 years of clinical experience with inactivated hepatitis A vaccine.
3. Safary A, André F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18, 57-67 (2000). Reviews 10 years of clinical experience with a recombinant hepatitis B vaccine.
4. Abraham B, Baine Y, De-Clercq N et al. Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine. Antiviral Res. 53(1), 63-73 (2002). Absence of interference between hepatitis A and B antigens.
5. Treadwell T. Trends in travel. In: Principles and practices of travel medicine. Zuckerman J (Ed.), John Wiley & Sons Inc., UK (2001).
6. Scoville SL, Bryan JP, Tribble D et al. Epidemiology, preventive services and illnesses of international travelers. Mil. Med. 162, 172-178 (1997).
7. Carson PJ, Nichol KL, O'Brien J, Hilo P, Janoff EN. Immune function and vaccine responses in healthy advanced elderly patients. Arch. Intern. Med. 10, 160(13), 2017-2024 (2000).
8. Paganelli R, Scala E, Quinti I, Ansotegui IJ. Humoral immunity in aging. Aging (Milano) 6, 143-150 (1994).
9. Treadwell T, Keeffe E, Lake J et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am. J. Med. 95(6), 584-588 (1993).
10. Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17(13-14), 1657-1662 (1999). Review of pivotal data with Twinrix vaccine in Europe.
11. Joines RW, Blatter M, Abraham B et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine 19, 4710- 4719 (2001). Review of pivotal data with Twinrix vaccine in the USA.
12. Delem A, Safary A, De Namur F, Hauser P, D'Hondt E. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A. Vaccine 11 (4), 479-484 (1993).
13. Hadler SC, Francis DP, Maynard JE et al. Long-term inimunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315 (4), 209-214 (1986).
14. Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol. 65 (1), 6-13 (2001). Long-term follow-up data with Twinrix in adults and children.
15. Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A. Simultaneous passive and active immunization against hepatitis A. Vaccine 10(Suppl 1), S138-141 (1992).
16. Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J. Med. Virol. 40(1), 22-27 (1993).
17. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am. J. Prev. Med. 15, 1-8 (1998).
18. Shaw FE Jr, Guess HA, Roets JM et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 7(5), 425-430 (1989).
19. Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated, alumadjuvanted hepatitis A vaccine in healthy adults. Vaccine 15(10), 1157-61 (1997).
20. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18(Suppl. 2), S51-55 (1993).
21. Koff RS Immunogenicity of hepatitis B vaccines: implications of immune memory Vaccine 20, 3695-3701 (2002). Review of immunogenicity data for several hepatitis B vaccines.
22. Rendi-Wagner P, Kundi M, Stemberger H et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19(15-16), 2055-2060 (2001). Comparative data with combined hepatitis A and B vaccine in a real-life situation.
23. Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hep. Rev. 5(2), 77-88 (1999).